Novartis AG http://www.alacrastore.com/company-snapshot/Novartis_AG-1014770 28 Nov 2009 08:57:16 EST 1014770 Novartis AG en AlacraStore RSS Builder 1.0 30 http://www.alacrastore.com/storecontent/newstex/BW-0001-39995648BW-0001-39995648newstex/BW-0001-39995648xmlNewstex Inc.2005Idera Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.Newstex Inc.newstex.comnewstexBW-0001-39995648Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007005000040000000400200004002006070030000700300107014000070140120701400613000000130100001301000525 Nov 2009 08:17:40 EST180000001802200011/25/2009 Nov. ##, #### (Business Wire) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February ##, ####. “We appreciate the...IDERA PHARMACEUTICALS INCMERCK & CO INCMERCK KGAANOVARTIS AGSUDHIR AGRAWALIDRAMKGAYMRKNVSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-39989960BW-0001-39989960newstex/BW-0001-39989960xmlNewstex Inc.2005Incyte CorporationNewstex Inc.newstex.comnewstexBW-0001-39989960Business Wire0001Business WireBW1Newstex Inc.Business Wire0700000007005000040000000400200004002006070140000701400807014007070010000700100425 Nov 2009 02:17:39 EST180000001802200011/25/2009 Nov. ##, #### (Business Wire) -- Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB#####,...INCYTE CORPNOVARTIS AGPAUL A FRIEDMANINCYNVSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-39989972HUG-0001-39989972newstex/HUG-0001-39989972xmlNewstex Inc.2005Copyright (c) Hugin AS 2009. All rights reserved.Novartis International AGNewstex Inc.newstex.comnewstexHUG-0001-39989972Hugin AS0001Hugin ASHUG1Newstex Inc.Hugin AS040000000400200004002006040160000401600504006000040060050700000007001000070010040701400007014008070140120701400702000000020020000200200625 Nov 2009 02:17:39 EST1800000018016000180220001900200711/25/2009 Nov. ##, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------...NOVARTIS AGNVSNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/T2537273T2537273ccbn/T2537273norm10 Nov 2009 08:06:00 EST2537273Final Transcript of NVS presentation, 9-Nov-09 1:00pm ETNovartis AG54.0000FinalNovartis AG at Thomson Reuters Global Health Summit TranscriptNVS1:00pm ETTranscript...Thomson Reuters Media (Audio begins in progress) You didn't do it, you know, just for no reason as charity. There was the fear (multiple speakers). Joe Jimenez - Novartis AG - CEO Pharmaceuticals You're right. I think one of the benefits is that we went and we said that -- we made a decision as an industry to become part of a solution early. And I do think there was a benefit there in terms of decisions that could be made and could not have been made. But I wouldn't want to speculate on any individual piece. It was, I think, the pharma industry's willingness to be part of a solution. Thomson Reuters Media So it is pretty much a preventative step. Get in there early, maybe you don't end up going the way of the health insurers. Joe Jimenez - Novartis AG - CEO Pharmaceuticals I wouldn't call it preventative either. It is coming at a significant cost. This is a significant cost to the pharmaceutical industry when you add up the numbers, without the benefit of a significant amount of additional... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/HIN-0001-39597738HIN-0001-39597738newstex/HIN-0001-39597738xmlNewstex Inc.2005Newstex Inc.newstex.comnewstexHIN-0001-39597738The Hindu Business Line0001The Hindu Business LineHIN1Newstex Inc.Hindu Business Line1100000011006000040000000401600004016008040070000400700810 Nov 2009 02:20:25 EST180000001800700019000000190020001900200411/10/2009 Nov. ##, #### ( The Hindu Business Line delivered by Newstex) -- Our Bureaus Ms Nooyi added that the company would continue to focus on products and solutions with a focus on India. “You cannot just import Western solutions to...COLGATE PALMOLIVE COGOOGLE INC.NOVARTIS AGPEPSICO INCARTHUR C MARTINEZDANIEL VASELLAIAN M COOKJAMES J SCHIRORAY L HUNTSHARON PERCY ROCKEFELLERShona L BrownVICTOR J DZAUCLGOOGNVSPEPNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-39579981MW-0001-39579981newstex/MW-0001-39579981xmlNewstex Inc.2005Copyright (c) 2009, Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited.Sernova Corp.LONDON, ONTARIONewstex Inc.newstex.comnewstexMW-0001-39579981Marketwire0001MarketwireMW1Newstex Inc.Marketwire1100000011006000040000000400200004002006040160000401600813000000130010001300100207000000070140000701401210 Nov 2009 07:20:15 EST18000000180070001900000019002000190020121900200711/10/2009 LONDON, ONTARIO, Nov. ##, #### (Marketwire delivered by Newstex) -- LONDON, ONTARIO -- (Marketwire) -- ##/##/## -- Sernova Corp. ("Sernova" or the "Company" or the "Corporation") (TSX VENTURE: SVA). Dr. George Adams, Chairman of the...NOVARTIS AGSERNOVA CORPNVSSEOVFSVANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/CCN-0001-39581229CCN-0001-39581229newstex/CCN-0001-39581229xmlNewstex Inc.2005Copyright (c) 2009 - Marketwire.Sernova Corp.Newstex Inc.newstex.comnewstexCCN-0001-39581229Marketwire Canada0001Marketwire CanadaCCN1Newstex Inc.Marketwire Canada XPath040000000400200004002006040160000401600813000000130010001300100207000000070140000701401210 Nov 2009 07:20:14 EST18000000180070001900000019002000190020121900200711/10/2009 LONDON, ONTARIO, Nov. ##, #### (Marketwire delivered by Newstex) -- Sernova Corp. ("Sernova" or the "Company" or the "Corporation") (TSX VENTURE:SVA). Dr. George Adams, Chairman of the Board of Directors is pleased to announce the appointment...NOVARTIS AGSERNOVA CORPNVSSEOVFSVANewsNewstexCHINA - Novartis AG of Switzerland planned to acquire a ##% interest in Zhejiang Tianyuan Bio- Pharmaceutical Co, a Zhejiang- based manufacturer of vaccines, for CNY ### mil (USD ###.### mil).06 Nov 2009 12:22:15 EST66987V99107Q66987V99107QNovartis AGZhejiang Tianyuan Bio-pharmaceutical Co LtdNovartis AGZhejiang Tianyuan Bio-pharmaceutical Co Ltdhttp://www.alacrastore.com/storecontent/Thomson_M%26A/Novartis_AG_acquires_Zhejiang_Tianyuan_Bio_pharm_Co-2124838040sdc/21248380402124838040Copyright © 2009, Thomson Financial, All Rights ReservedZurichDrugsSwitzerlandPharmaceutical preparations2834FFForeignPublicNOVZN2023:Dry, condensed, and evaporated dairy products2032:Canned specialties2834:Pharmaceutical preparations3851:Ophthalmic goods6719:Offices of holding companies, nec2023:Dry, condensed, and evaporated dairy products2032:Canned specialties2834:Pharmaceutical preparations3851:Ophthalmic goods6719:Offices of holding companies, necDrugsChinaPharmaceutical preparations2834FFForeignPrivate5297002Mnfr pharmMnfr vaccinesCashCash OnlyStock984700001Nov 6 20090.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000SFR30 Sep 090.000008293.592000.0000044683.1270090686.00300Swiss Franc0.000001.000002.000003.000004.000005.000006.000007.000008.000009.0000010.0000011.0000012.0000013.00000Novartis AG, headquartered inBasel, Switzerland,manufactures pharmaceuticalsincluding self-medications andnon-prescription drugs. Italso manufactures optical andophthalmic products includingcontact lenses. The companyproduces nutritional productsincluding baby formula andbaby canned food and serves asa holding company. It wasfounded in 1996.Novartis AG, headquartered in Basel, Switzerland,manufactures pharmaceuticals including self-medications andnon-prescription drugs. It also manufactures optical andophthalmic products including contact lenses. The companyproduces nutritional products including baby formula andbaby canned food and serves as a holding company. It wasfounded in 1996.Novartis AG, headquartered in Basel, Switzerland, manufactures pharmaceuticals including self-medications and non-prescription drugs. It also manufactures optical and ophthalmic products including contact lenses. The company produces nutritional products including baby formula and baby canned food and serves as a holding company. It was founded in 1996.1.000002.000003.000004.000005.000006.000007.00000Zhejiang TianyuanBio-pharmaceutical Co Ltd,located in Hangzhou, China,manufactures vaccines forepidemic hemorrhagic fever andinfluenza. The company wasfounded in 1989.Zhejiang Tianyuan Bio-pharmaceutical Co Ltd, located inHangzhou, China, manufactures vaccines for epidemichemorrhagic fever and influenza. The company was founded in1989.Zhejiang Tianyuan Bio-pharmaceutical Co Ltd, located in Hangzhou, China, manufactures vaccines for epidemic hemorrhagic fever and influenza. The company was founded in 1989.0.000000.000000.000000.00000YChinese Yuan04 Nov 09Wed, 04 Nov 2009 00:00:00 ESTDate Announced: 11/04/2009Date Effective:Acq. Maj. Int.Friendly0.000000.000000.000001000.000000.000000.00000Price/Share0.00000850 Chinese Yuan850.000001000.00000850 Chinese Yuan850.000000.000000.000000.000000.00000850.00000850 Chinese Yuan0.14600N75.190000.000000.000000.000000.000000.00000124.51500124.515000.000000.000000.000000.000000.000000.000000.000000.0000085.000000.000000.000000.000000.000000.000000.000000.000000.00000130770.711000.000000.000000.00000146.488000.000000.000000.000000.000000.000000.000000.000000.000000.000001.000002.000003.000004.000005.000006.000007.000008.00000CHINA - Novartis AG ofSwitzerland planned toacquire a 85% interest inZhejiang Tianyuan Bio-Pharmaceutical Co, a Zhejiang-based manufacturer ofvaccines, for CNY 850 mil(USD 124.515 mil).CHINA - Novartis AG of Switzerland planned to acquire a 85% interest in Zhejiang Tianyuan Bio- Pharmaceutical Co, a Zhejiang- based manufacturer of vaccines, for CNY 850 mil (USD 124.515 mil).CHINA - Novartis AG of Switzerland planned to acquire a 85% interest in Zhejiang TianyuanBio- Pharmaceutical Co, a Zhejiang- based manufacturer of vaccines, for CNY 850 mil (USD124.515 mil).CHINA - Novartis AG of Switzerland planned to acquire a 85% interest in Zhejiang Tianyuan Bio- Pharmaceutical Co, a Zhejiang- based manufacturer of vaccines, for CNY 850 mil (USD 124.515 mil).CHINA - Novartis AG of Switzerland planned to acquire a 85% interest in Zhejiang Tianyuan Bio- Pharmaceutical Co, a Zhejiang- basedmanufacturer of vaccines, for CNY 850 mil (USD 124.515 mil).Pending55232.268008592.1610046291.7180093950.696000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.00000Status:Pending-999.00000np0.00000-999.00000np0.000000.000000.000000.000000.000000.000000.000000.000000.000000.000000.000002833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances5297002ZurichSwitzerland2834ForeignPublicNOVZN2833:Medicinal chemicals and botanical products2834:Pharmaceutical preparations2836:Biological products, except diagnostic substances984700001China2834ForeignPrivate124.51500850.00000124.5150075.19000Deal InformationTF Mergers & Acquisitionshttp://www.alacrastore.com/storecontent/newstex/BW-0001-39425660BW-0001-39425660newstex/BW-0001-39425660xmlNewstex Inc.2005Opexa Therapeutics, Inc.Newstex Inc.newstex.comnewstexBW-0001-39425660Business Wire0001Business WireBW1Newstex Inc.Business Wire070000000700500014000000140160000900000009015000040000000400200004002006040020010401600004016018040160480401600104016005040160031300000013002000130020051301000013010005130010001300100207014000070140040701401211000000110160001101600104 Nov 2009 09:25:05 EST180000001800400018008000180180001801600011/4/2009 Nov. #, #### (Business Wire) -- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the quarter ended September ##, ####, and provided...NOVARTIS AGOPEXA THERAPEUTICS INC.Neil K WarmaNVSOPXANewsNewstexhttp://www.alacrastore.com/storecontent/newstex/HUG-0001-39424037HUG-0001-39424037newstex/HUG-0001-39424037xmlNewstex Inc.2005Copyright (c) Hugin AS 2009. All rights reserved.Novartis International AGNewstex Inc.newstex.comnewstexHUG-0001-39424037Hugin AS0001Hugin ASHUG1Newstex Inc.Hugin AS07000000070030000700300607014000070140120400000004016000040160050400200004002006040060000400600502000000020020000200200613000000130100001301000504 Nov 2009 08:26:58 EST18000000180160001802000019000000190020001900200919002004190020131900200711/4/2009 Nov. #, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ------------------------------------------------------------------...NOVARTIS AGDaniel VasellaNVSNewsNewstexhttp://www.alacrastore.com/research/fitch-ratings-Fitch_European_Pharma_Faces_Declining_Profitability_on_Diversification_Pressures-524736_pr_frame524736_pr_framefitch/524736_pr_framehtmlAstraZeneca plcBayer AGGlaxosmithkline Finance PlcGlaxoSmithKline plcNovartis AGRoche Holding Ltd.Sanofi-Aventis S.A.Smithkline Beecham Corporation803624348045797280457976804579798110870781108717825886838588407329 Oct 2009 10:17:00 EST0103170085Press ReleaseAZNBAYNGSKNOVNROSANFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.ARGCHEDEUESPFRAGBRINDMEXRUSUSA010100000101010001020000010300000103100001031700020200000300000003010000030108000302000003030000040000000401000004020000Credit & Investment ResearchFitch Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-Novartis_AG-753964753964spcred/753964normglobalstructured28 Oct 2009 03:35:00 EST400Full ReportThe latest Full Report from S&PPharmaceuticalsAsiaEurope, Middle East, AfricaLatin AmericaUnited StatesGlobal IssuersStructured FinanceFull ReportCHE66987V35202010 352020 3520 35Novartis AG313022NOVN@VXFULLBMUCHEFRAGBRJPNUSA04635304635P6698M36698M46698M571708171708C71708D71708E71708F8010M28010M38010M5874058U7170835201010 352010 3520 3535202010 352020 3520 35AstraZeneca PLCChiron Corp.GlaxoSmithKline PLCJohnson&JohnsonMerck&Co. Inc.Novartis Finance Corp.Novartis Groupe France S.A.Novartis Securities Investment Ltd.Pfizer Inc.Roche Holding AGsanofi-aventis S.A.Takeda Pharmaceutical Co. Ltd.1012561014831018631160041161551186776698M266989G58933W58933V58933U58933T58933S58933R58933N58933147816G47816F47816E47816D47816037734037733W17004004635RUSALATAMERICAEUROMIDAFRASIASwitzerland126474309443348380354926357156395852ASIAEUROMIDAFRLATAMERICAUSA225454Z@FP4502@JP7157ZAZN@LNCHIRGSK@LNJNJMRKPFEROG@VXSAN@FPABSConsumerCORPFIGLOBISSHealthSTRUCCredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/research/s-and-p-credit-research-Summary_Novartis_AG-753965753965spcred/753965normglobalstructured28 Oct 2009 03:35:00 EST175SummaryThe latest Summary from S&PSwitzerlandPharmaceuticalsAsiaEurope, Middle East, AfricaLatin AmericaUnited StatesGlobal IssuersStructured FinanceSummaryCHE66987V35202010 352020 3520 35Novartis AG313022ASIAEUROMIDAFRLATAMERICAUSANOVN@VXSUMMARYCHEFRAGBRJPNUSA04635304635P874058U7170835202010 352020 3520 35AstraZeneca PLCGlaxoSmithKline PLCJohnson&JohnsonMerck&Co. Inc.Pfizer Inc.Roche Holding AGsanofi-aventis S.A.Takeda Pharmaceutical Co. Ltd.101256101483101863116155126474348380357156395852ASIAEUROMIDAFR8010M54502@JPAZN@LNGSK@LNJNJMRKPFEROG@VXSAN@FPABSConsumerCORPFIGLOBISSHealthSTRUC8010M38010M271708F71708E71708D71708C71708158933W58933V58933U58933T58933S58933R58933N58933147816G47816F47816E47816D47816037734037733W04635RUSACredit & Investment ResearchS&P Credit Researchhttp://www.alacrastore.com/research/fitch-ratings-Novartis_AG-476308_report_frame476308_report_framefitch/476308_report_framepdfNovartis AG8045797626 Oct 2009 10:11:00 EST01031700165Credit UpdateNOVNFitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.ARGCHEDEUESPGBRINDMEXRUSUSA010100000101010001020000010300000103100001031700020200000300000003010000030108000302000003030000040000000401000004020000Credit & Investment ResearchFitch Researchhttp://www.alacrastore.com/storecontent/ccbn/B2047667B2047667ccbn/B2047667norm22 Oct 2009 05:09:00 EST2047667Edited Brief of NVS earnings conference call or presentation, 22-Oct-09 2:00pm CETNovartis AG54.0000EditedNovartis Corporation Q3 2009 Earnings Conference Call SummaryNVS2:00pm CETBrief...Daniel Vasella Novartis Corporation - Chairman & CEO John Gilardi Novartis Corporation - IR Raymund Breu Novartis Corporation - CFO Joe Jimenez Novartis Corporation - CEO, Pharmaceuticals Trevor Mundel Novartis Corporation - Global Head of Development Pharma Andrin Oswald Novartis Corporation - CEO, Vaccines and Diagnostics David Epstein Novartis Corporation - Oncology, President & CEO Jeff George Sandoz - CEO George Gunn Novartis Corporation - CEO, Consumer Health... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/ccbn/T2047667T2047667ccbn/T2047667norm22 Oct 2009 01:09:00 EST2047667Final Transcript of NVS earnings conference call or presentation, 22-Oct-09 2:00pm CETNovartis AG54.0000FinalNovartis Corporation Q3 2009 Earnings Conference Call TranscriptNVS2:00pm CETTranscript...Daniel Vasella Novartis Corporation - Chairman & CEO John Gilardi Novartis Corporation - IR Raymund Breu Novartis Corporation - CFO Joe Jimenez Novartis Corporation - CEO, Pharmaceuticals Trevor Mundel Novartis Corporation - Global Head of Development Pharma Andrin Oswald Novartis Corporation - CEO, Vaccines and Diagnostics David Epstein Novartis Corporation - Oncology, President & CEO Jeff George Sandoz - CEO George Gunn Novartis Corporation - CEO, Consumer Health... Credit & Investment ResearchThomson StreetEventshttp://www.alacrastore.com/storecontent/newstex/HUG-0001-39048294HUG-0001-39048294newstex/HUG-0001-39048294xmlNewstex Inc.2005Copyright (c) Hugin AS 2009. All rights reserved.Novartis International AGNewstex Inc.newstex.comnewstexHUG-0001-39048294Hugin AS0001Hugin ASHUG1Newstex Inc.Hugin AS0400000004018000040170000100000001021000070000000700300007003006070030010701400007014012070140080700100007001007040020000400200604016000040160180401604804016003040060000400600513000000130100001301000522 Oct 2009 02:21:34 EST180000001800400018020000180080001800200018016000190000001900200019002004190020071900200919002013190020101900201510/22/2009 Oct. ##, #### (Hugin AS delivered by Newstex) -- Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------...ALCON INCNOVARTIS AGDaniel VasellaACLNVSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/BW-0001-38813479BW-0001-38813479newstex/BW-0001-38813479xmlNewstex Inc.2005Mintz LevinNewstex Inc.newstex.comnewstexBW-0001-38813479Business Wire0001Business WireBW1Newstex Inc.Business Wire0400000004002000040020060401600004016013070000000700300007003001070140000701401213000000130100001301000514 Oct 2009 04:22:55 EST18000000180220001801500010/14/2009 Oct. ##, #### (Business Wire) -- Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. represented its client, Paratek Pharmaceuticals, Inc. in a worldwide licensing agreement with Novartis for its late-stage antibiotic, PTK ####. The...NOVARTIS AGNVSNewsNewstexhttp://www.alacrastore.com/storecontent/newstex/MW-0001-38638168MW-0001-38638168newstex/MW-0001-38638168xmlNewstex Inc.2005Copyright (c) 2009, Marketwire. All rights reserved. All the news releases provided by Market Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited.RetroVirox Inc.SAN DIEGO, CANewstex Inc.newstex.comnewstexMW-0001-38638168Marketwire0001MarketwireMW1Newstex Inc.Marketwire09000000090150000400000004002000040020060401600004016008070000000701400007014012070030000700300113000000130100001301000508 Oct 2009 08:22:49 EST180000001800700019000000190010001900100510/8/2009 SAN DIEGO, CA, Oct. #, #### (Marketwire delivered by Newstex) -- SAN DIEGO, CA -- (Marketwire) -- ##/##/## -- RetroVirox, Inc., a biotechnology company focused on developing novel antivirals, announced today the appointment of Ronald...ASTRAZENECA PLCGLAXOSMITHKLINE PLCNOVARTIS AGAZNGSKNVSNewsNewstexhttp://www.alacrastore.com/storecontent/ccbn/B2468549B2468549ccbn/B2468549norm30 Sep 2009 12:06:00 EST2468549Edited Brief of NVS conference call or presentation, 30-Sep-09 2:00pm CETNovartis AG54.0000EditedNovartis AG FTY720 Phase III FREEDOMS Trial Results Conference Call SummaryNVS2:00pm CETBrief...Trevor Mundel Novartis AG - Global Head of Development, Novartis Pharma Gordon Francis Novartis AG - Head Clinical Science Unit, NeuroImmunology CONFERENCE CALL PARTICIPANTS... Credit & Investment ResearchThomson StreetEvents